At a glance
ClinicalIndex Comparison RecordN/ACompleted· 22 enrolled
Drug / intervention
MRI Tracerdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Fatty Liver on TCA Cycle Flux and the Pentose Phosphate Pathway (HP FFF)
University of Texas Southwestern Medical Center·observational·Posted Mar 29, 2018·Updated Feb 19, 2025
In Brief
An observational study evaluating MRI Tracer for Fatty Liver. Completed, enrolled 22 participants across 1 site.
Detailed Summary
The investigators plan to evaluate sensitivity and specificity of HP 13C-pyruvate as an imaging agent for detection of altered PDH flux in fatty liver.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsFatty Liver
CountriesUnited States
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedMar 2018
Enrollment StartOct 2018
Primary CompletionOct 2023
TodayJul 2026
First PostedMar 29, 2018
Enrollment StartOct 1, 2018
Primary CompletionOct 13, 2023
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 8.3 years ago
Interventions
MRI Tracerdrug
Hyperpolarized \[1-13C\] pyruvate for injection under IND133229 used to enhance MRI/MRS/MRSI using a 3T MRI scanner.